Landis+Gyr Announces Second Quarter and First Half FY 2026 Financial Results

Landis+Gyr reported first-half FY2026 revenue of $501.4 million, down 6.3% year over year, while adjusted EBITDA rose 3.5% to $73.9 million and adjusted gross margin expanded 370 basis points to 37.7%. The company raised its FY2026 adjusted EBITDA margin guidance to 15.0%–16.0%, narrowed its revenue outlook to $1,085–$1,115 million, and reported a $509 million order intake from a major contract awarded after the half-year close. It also completed $175 million in share repurchases.

Analysis

The key tension is improving profitability against weak underlying order replenishment. The October award is large enough to change the near-term book-to-bill picture, but it may mask soft demand elsewhere and creates execution and customer-concentration risk; verify award scope, delivery phasing, and cancellation terms before capitalizing it as durable growth. The $3.7bn backlog supports visibility, not necessarily near-term revenue or margins, particularly through customer-deployment transitions.

Near term, the raised EBITDA-margin range is supportive, but the top-line outlook remains constrained. If second-half deployments ramp as guided, operating leverage can sustain the margin improvement; if revenue slips, the margin upgrade may prove mix- or cost-driven and less repeatable. Track quarterly order intake excluding the October award, revenue conversion, and working-capital cash conversion. Itron is a relevant competitive read-through: sustained utility spending would support the sector, while LAND-specific order weakness would point to share or timing issues.

Over 6–18 months, a U.S. listing could broaden investor access, but it is a potential catalyst, not an earnings driver; timing and incremental liquidity are unverified. The completed buyback may support near-term demand, though returning divestment proceeds is not recurring cash generation. The contrarian risk is treating record gross margin and one major award as proof of a broad-based demand recovery.

Key Decisions for Investors

• Do not chase a post-release spike. Consider a modest, staged long in LAND only if subsequent reporting confirms deployment ramp and order intake improves beyond the one-off October award; this offers margin-upside exposure while limiting reliance on the contract headline.
• Set the thesis check at the next results: watch revenue conversion, adjusted EBITDA margin, and order intake excluding the major award. Reassess or reduce if the company misses its narrowed revenue outlook, margins fall below its raised range, or orders remain weak.
• Treat U.S.-listing progress as a watch catalyst rather than underwriting a valuation uplift before filing, timetable, and expected trading/liquidity details are disclosed. Avoid assuming the buyback can repeat without new recurring cash generation.